Literature DB >> 19561125

Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria.

David Hermanson1, Sadiya N Addo, Anna A Bajer, Jonathan S Marchant, Sonia Goutam Kumar Das, Balasubramanian Srinivasan, Fawaz Al-Mousa, Francesco Michelangeli, David D Thomas, Tucker W Lebien, Chengguo Xing.   

Abstract

HA 14-1 is a small-molecule Bcl-2 antagonist that promotes apoptosis in malignant cells, but its mechanism of action is not well defined. We recently reported that HA 14-1 has a half-life of only 15 min in vitro, which led us to develop a stable analog of HA 14-1 (sHA 14-1). The current study characterizes its mode of action. Because of the antiapoptotic function of Bcl-2 family proteins on the endoplasmic reticulum (ER) and mitochondria, the effect of sHA 14-1 on both organelles was evaluated. sHA 14-1 induced ER calcium release in human leukemic cells within 1 min, followed by induction of the ER stress-inducible transcription factor ATF4. Similar kinetics and stronger intensity of ER calcium release were induced by the sarcoendoplasmic reticulum Ca(2+)-ATPase (SERCA) inhibitor thapsigargin, accompanied by similar kinetics and intensity of ATF4 induction. sHA 14-1 directly inhibited SERCA enzymatic activity but had no effect on the inositol triphosphate receptor. Evaluation of the mitochondrial pathway showed that sHA 14-1 triggered a loss of mitochondrial transmembrane potential (Delta psi m) and weak caspase-9 activation, whereas thapsigargin had no effect. (R)-4-(3-Dimethylamino-1-phenylsulfanylmethyl-propylamino)-N-{4-[4-(4'-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-3-nitrobenzenesulfonamide (ABT-737), a well established small-molecule Bcl-2 antagonist, rapidly induced loss of Delta psi m and caspase-9 activation but had no effect on the ER. The pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone had some protective effect on sHA 14-1-induced cell death. These collective results suggest a unique dual targeting mechanism of sHA 14-1 on the apoptotic resistance machinery of tumor cells that includes antiapoptotic Bcl-2 family proteins and SERCA proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561125      PMCID: PMC2730395          DOI: 10.1124/mol.109.055830

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  66 in total

Review 1.  Bcl-2 on the endoplasmic reticulum: protecting the mitochondria from a distance.

Authors:  Michael J Thomenius; Clark W Distelhorst
Journal:  J Cell Sci       Date:  2003-11-15       Impact factor: 5.285

Review 2.  Regulation of apoptosis by endoplasmic reticulum pathways.

Authors:  David G Breckenridge; Marc Germain; Jaigi P Mathai; Mai Nguyen; Gordon C Shore
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

3.  The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.

Authors:  X-Y Pei; Y Dai; S Grant
Journal:  Leukemia       Date:  2003-10       Impact factor: 11.528

4.  Anti-apoptotic protein Bcl-2 interacts with and destabilizes the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA).

Authors:  Elena S Dremina; Victor S Sharov; Keshava Kumar; Asma Zaidi; Elias K Michaelis; Christian Schöneich
Journal:  Biochem J       Date:  2004-10-15       Impact factor: 3.857

5.  Enhancement of stress-induced apoptosis in B-lineage cells by caspase-9 inhibitor.

Authors:  Nisha Shah; Rebecca J Asch; Alana S Lysholm; Tucker W Lebien
Journal:  Blood       Date:  2004-07-08       Impact factor: 22.113

6.  HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.

Authors:  J D Lickliter; N J Wood; L Johnson; G McHugh; J Tan; F Wood; J Cox; N W Wickham
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

7.  A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

Authors:  Yun Dai; Mohamed Rahmani; Seth J Corey; Paul Dent; Steven Grant
Journal:  J Biol Chem       Date:  2004-06-02       Impact factor: 5.157

8.  Critical upstream signals of cytochrome C release induced by a novel Bcl-2 inhibitor.

Authors:  Jing An; Yingming Chen; Ziwei Huang
Journal:  J Biol Chem       Date:  2004-02-13       Impact factor: 5.157

9.  Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate.

Authors:  Rui Chen; Ignacio Valencia; Fei Zhong; Karen S McColl; H Llewelyn Roderick; Martin D Bootman; Michael J Berridge; Stuart J Conway; Andrew B Holmes; Gregory A Mignery; Patricio Velez; Clark W Distelhorst
Journal:  J Cell Biol       Date:  2004-07-19       Impact factor: 10.539

10.  Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis.

Authors:  Wei-Xing Zong; Chi Li; Georgia Hatzivassiliou; Tullia Lindsten; Qian-Chun Yu; Junying Yuan; Craig B Thompson
Journal:  J Cell Biol       Date:  2003-07-07       Impact factor: 10.539

View more
  20 in total

Review 1.  Endoplasmic-reticulum calcium depletion and disease.

Authors:  Djalila Mekahli; Geert Bultynck; Jan B Parys; Humbert De Smedt; Ludwig Missiaen
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

2.  HA14-1, but not the BH3 mimetic ABT-737, causes Ca2+ dysregulation in platelets and human cell lines.

Authors:  Haidar Akl; Ilse Vandecaetsbeek; Giovanni Monaco; Alexandre Kauskot; Tomas Luyten; Kirsten Welkenhuyzen; Marc Hoylaerts; Humbert De Smedt; Jan B Parys; Geert Bultynck
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

3.  CXL146, a Novel 4H-Chromene Derivative, Targets GRP78 to Selectively Eliminate Multidrug-Resistant Cancer Cells.

Authors:  Tengfei Bian; Abderrahmane Tagmount; Christopher Vulpe; Kavitha Chandagirikoppal Vijendra; Chengguo Xing
Journal:  Mol Pharmacol       Date:  2020-04-10       Impact factor: 4.436

4.  ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.

Authors:  Roberta Traini; Gal Ben-Josef; Diana V Pastrana; Elizabeth Moskatel; Ashima K Sharma; Antonella Antignani; David J Fitzgerald
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

5.  A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML.

Authors:  Nicholas P Bleeker; Razvan L Cornea; David D Thomas; Chengguo Xing
Journal:  Mol Pharm       Date:  2013-09-30       Impact factor: 4.939

6.  Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.

Authors:  Justus Lieber; Verena Ellerkamp; Julia Wenz; Bettina Kirchner; Steven W Warmann; Jörg Fuchs; Sorin Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-02       Impact factor: 1.827

7.  Discovery of enzyme modulators via high-throughput time-resolved FRET in living cells.

Authors:  Simon J Gruber; Razvan L Cornea; Ji Li; Kurt C Peterson; Tory M Schaaf; Gregory D Gillispie; Russell Dahl; Krisztina M Zsebo; Seth L Robia; David D Thomas
Journal:  J Biomol Screen       Date:  2014-02

8.  Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.

Authors:  Nelly Buron; Mathieu Porceddu; Magali Brabant; Diana Desgué; Cindy Racoeur; Myriam Lassalle; Christine Péchoux; Pierre Rustin; Etienne Jacotot; Annie Borgne-Sanchez
Journal:  PLoS One       Date:  2010-03-31       Impact factor: 3.240

9.  Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.

Authors:  Sonia G Das; David L Hermanson; Nicholas Bleeker; Xazmin Lowman; Yunfang Li; Ameeta Kelekar; Chengguo Xing
Journal:  ACS Chem Biol       Date:  2012-11-05       Impact factor: 5.100

10.  Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.

Authors:  Gopalakrishnan Aridoss; Bo Zhou; David L Hermanson; Nicholas P Bleeker; Chengguo Xing
Journal:  J Med Chem       Date:  2012-05-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.